Received Jul 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 2N795 | IM |
Intramuscular Administration of Priorix (Inappropriate Route of Administration); This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a 64-year-old female patient who received MMR (Priorix) (batch number 2N795, expiry date 13-SEP-2026) for prophylaxis. On 01-JUL-2025, the patient received the 1st dose of Priorix (intramuscular). On 01-JUL-2025, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: Intramuscular Administration of Priorix (Inappropriate Route of Administration)). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 01-JUL-2025 The pharmacist called to ask for information/advise about the administration of Priorix intramuscularly instead of subcutaneously which led to subcutaneous injection formulation administered by other route. Vaccination date, vaccine detail and patient demographics were obtained in this call (only no patient initials provided from the Pharmacist end). No further information was obtained in this call. The vaccine administration facility was the same as primary reporter.